secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001193125-23-040742
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phase 2 interim data: 100% tumor control, 88% vision preservation with bel-sar in early choroidal melanoma
--------------------------------------------------------------------------------

- 100% tumor control (8/8) and 88% visual acuity preservation in patients receiving three cycles of bel-sar.
- Statistically significant reduction in tumor growth rate: -0.289 mm/yr (p<0.0001) vs. each patient's documented rate.
- No treatment-related SAEs; only mild anterior inflammation (Grade 1) in 20% of patients.
- Company plans to initiate global Phase 3 trial enrollment this year based on these data.
- Data presented at Macula Society 46th Annual Meeting with average 9 months follow-up.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312523040742/0001193125-23-040742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312523040742/d460344d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-040742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer